KLF5 and ovarian carcinoma: Indeed, Dex has been shown to reduce the anticancer effects of a drug [27], and can create resistance to chemotherapy through different mechanisms, for example by increasing the adhesion of human ovarian cancer cell lines to the extracellular matrix [52] or by up-regulating Krüppel-like factor 5 in triple-negative breast cancer [53].